Trial Profile
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Dasiglucagon (Primary)
- Indications Hypoglycaemia; Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Zealand Pharma
- 26 Jun 2023 According to a Zealand Pharma media release, the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for dasiglucagon injection for the treatment of severe hypoglycemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
- 01 Oct 2021 Results assessing efficacy and safety of dasiglucagon when administered via an autoinjector device published in the Diabetes, Obesity and Metabolism
- 29 Jun 2021 Results (n=253) of three randomized, placebo-controlled phase 3 trials (2 in adults and 1 in pediatric subjects), presented at the 81st Annual Scientific Sessions of the American Diabetes Association